Warren Buffett knows what he likes -- and he gets what he likes. While he is widely known for investing in consumer product companies, another industry has also captured his attention and his money. Here are three things Buffett really likes about health care.
1. Keep it simple
Buffett likes to keep things simple and understand the business before he buys. DaVita Healthcare Partners is a great example of this desired simplicity. The company provides dialysis services for patients with chronic kidney disease or end stage renal disease. Patients with these diseases can't survive without dialysis. DaVita provides the service. It doesn't get much more simple than that.
Buffett's Berkshire Hathaway owns 14% of DaVita, valued at more than $1.9 billion and growing. The stock has a one-year return of nearly 34%.Keeping it simple can pay off.
2. Investing for the long run
Some might look at a company like GlaxoSmithKline and run for the hills. Just last year, the British pharma lost an estimated $35 billion in sales due to generic competition as key drugs lost patent protection. But Buffett first bought the stock in 2008 -- with full knowledge that the patent cliff was coming. Why? Buffett looks at the long run. His ideal holding period is "forever."
His position in GlaxoSmithKline isn't huge -- just 1.5 million shares valued at around $71 million. And the stock hasn't done much over the past year, with shares up only 2%. However, remember that Buffett is looking at the long run. Patents may come and go, but obviously Buffett still views Glaxo as a good long-term buy.
3. Buying businesses
Buffett doesn't buy a stock. He buys a business. His aim is to buy a "wonderful company at a fair price." Sanofi seems to have hit that mark. Berkshire Hathaway bought shares in the French pharmaceutical company back in 2006 and added to its position each year through 2010. Even through Sanofi's share prices were declining during much of that period, Buffett kept on buying. As with Glaxo, he saw the long-term potential for the business and cared less about how the stock was performing in the shorter term.
The short term has looked pretty good for Sanofi lately, though. Shares are up nearly 30% over the past year. While they're not up by nearly that much compared to 2006 levels, remember that Buffett kept adding to his position when shares were dropping. By focusing on buying the business, he has done quite well with his investment in Sanofi.
Liking with open eyes
Just because Warren Buffett likes an investment doesn't mean that he's blind to problems. For example, he cut back most of his position in Johnson & Johnson after J&J recalled products and encountered legal problems related to misleading doctors and patients about medication risks. Buffett commented that J&J still had "a lot of wonderful products and it's got a wonderful balance sheet" but that the company had made "too many mistakes."
We can't all be Warren Buffett, but we can learn from him. What he likes about health care can help us find other companies that we can like. But it's up to each of us to keep our eyes open -- and to take action. Like that other famous Mr. Buffett says (singer Jimmy Buffett): "People who think too much before they act don't act too much."
Warren Buffett referred to one macro trend as "the tapeworm that's eating at American competitiveness." Find out what it is in our free report: "What's Really Eating At America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The article 3 Things Buffett Likes About Health Care originally appeared on Fool.com.
Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Berkshire Hathaway and Johnson & Johnson. The Motley Fool owns shares of Berkshire Hathaway and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.